Now on Broadway: LanzaTech’s $2.2B SPAC merger takes the advanced bioeconomy’s biggest hit to an even bigger stage
In Illinois, news arrived that LanzaTech will go public in a merger with the NASDAQ-traded blank check firm AMCI Acquisition Corp II. The deal is reported to value the company at $2.2 billion. The transaction is expected to raise gross proceeds of approximately $275 million, comprised of AMCI’s $150 million of cash held in trust […]